Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-011-7 | CAS number: 552-38-5
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Gene Mutation in Bacteria- Not mutagenic (OECD TG 471)
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Dilithium Salicylate was examined for its potential to induce mutations in Salmonella typhimurium (TA1535, TA98, TA100, TA97a) and Escherichia coli (WP2 uvrA) bacterial cells, in both the presence and absence of an S9 metabolic activation system. Mutagenic properties have not been demonstrated and classification is not warranted.
Justification for classification or non-classification
The mutagenic potential of Lithium Salicylate was determined by read-across to Dilithium Salicylate. This read-across approach is based on the hypothesis that the hydrolysis of the dilithium salt of salicylic acid where the carboxylic acid and hydroxyl group are present in the metaisomer position would show similar biodegradation and toxicity patterns to the monolithium salt. The effect of the target substance (monolithium salt) is predicted based on the worst case approach as
complete dissociation into Salicylic acid and lithium hydroxide is expected with the source substance liberating two lithium ions.
Dilithium salicylate was not mutagenic to Salmonella typhimurium (TA1535, TA98, TA100, TA97a) or Escherichia coli (WP2 uvrA) bacterial cells in a reverse mutation assay. As the read-across is considered valid, these findings do not warrant classification of Lithium salicylate as a mutagen under the Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
